The EMA’s CHMP adopted the positive opinion recommending the approval of Opdivo + Pt-based CT for resectable NSCLC who are at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%
The opinion was based on the P-III trial (CheckMate -816) evaluating Opdivo (360mg, q3w) + CT vs CT alone which showed an improvement in EFS & pCR with 3 cycles of Opdivo + CT vs CT alone
The safety profile was consistent with prior reported studies while the 3yr. data showed a durable clinical benefit. The combination therapy was approved for resectable NSCLC regardless of PD-L1 expression levels in 21 countries, incl. the US, Japan & China, additional regulatory applications are under review by global health authorities
Ref: BMS | Image: BMS
Related News:- BMS to Present P-III Study (COMMANDS) of Reblozyl (luspatercept-aamt) as 1L Treatment of Anemia in Adults with Lower-Risk MDS at ASCO and EHA 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com